X @The Wall Street Journal

Regulatory Landscape - The Trump administration is intensifying its scrutiny of pharmaceutical advertising [1] - The administration's actions, while significant, did not escalate to the most severe measures anticipated by some pharmaceutical and advertising executives [1]